ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia

American Journal of Hematology

Volumn 90, Issue 7, 2015, Pages 653-656

  Elliott, Michelle A ^a   Pardanani, Animesh ^a   Hanson, Curtis A ^a   Lasho, Terra L ^a   Finke, Christy M ^a   Belachew, Alem A ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; ASXL1 PROTEIN; BILIRUBIN; CLADRIBINE; COLONY STIMULATING FACTOR RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR 3; HEMOGLOBIN; HYDROXYUREA; IMATINIB; RUXOLITINIB; THALIDOMIDE; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ASXL1 PROTEIN, HUMAN; CARRIER PROTEIN; CSF3R PROTEIN, HUMAN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; SETBP1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST TRANSFORMATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; CLINICAL ARTICLE; DISEASE COURSE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MIDDLE AGED; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SPLENOMEGALY; SWEATING; THROMBOCYTOPENIA; VERY ELDERLY; WEIGHT REDUCTION; GENE EXPRESSION; GENETICS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKEMIA, NEUTROPHILIC, CHRONIC; MORTALITY; MUTATION; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKEMIA, NEUTROPHILIC, CHRONIC; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; RECEPTORS, COLONY-STIMULATING FACTOR; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA;

EID: 84931829725     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24031     Document Type: Article

References (17)

1. Bain BJBR, Vardiman J, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissue: Chronic neutrophilic leukaemia. In: Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. 4th edn. International Agency for Research on Cancer (IARC): Lyon, p 80-812008.
2. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013;368:1781-1790. Prepublished on 2013/05/10 as DOI 10.1056/NEJMoa1214514.
3. Pardanani A, Lasho TL, Laborde RR, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013;27:1870-1873. Prepublished on 2013/04/23. as DOI 10.1038/leu.2013.122.
4. Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of jak2, CALR, or MPL in primary myelofibrosis. Blood 2014;124:1062-1069. Prepublished on 2014/07/06 as DOI 10.1182/blood-2014-05-578435.
5. Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014;123:e123-133. Prepublished on 2014/04/18 as. DOI 10.1182/blood-2014-02-554634.
6. Piazza R, Valletta S, Winkelmann N, et al. Recurrent setbp1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013;45:18-24. Prepublished on 2012/12/12 as. DOI 10.1038/ng.2495.
7. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and asxl1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients. Leukemia 2014;28:1494-1500. Prepublished on 2014/02/06 as. DOI 10.1038/leu.2014.57.
8. Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of ezh2 and asxl1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011;25:1200-1202. Prepublished on 2011/04/02 as. DOI 10.1038/leu.2011.58.
9. Tefferi A, Lasho TL, Finke CM, et al. CALR vs jak2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. Leukemia 2014;28:1472-1477. Prepublished on 2014/01/10 as DOI 10.1038/leu.2014.3.
10. Lasho TL, Mims A, Elliott MA, et al. Chronic neutrophilic leukemia with concurrent CSF3R and setbp1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. Leukemia, in press. Prepublished on 2014/01/22 as DOI 10.1038/leu.2014.39.
11. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506. Prepublished on 2011/07/01. as DOI 10.1056/NEJMoa1013343.
12. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:2428-2436. Prepublished on 2013/05/22 as DOI 10.1200/JCO.2012.47.3314.
13. Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and setbp1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients. Leukemia 2014;28:2206-2212. Prepublished on 2014/04/04. as DOI 10.1038/leu.2014.125.
14. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27:1861-1869. Prepublished on 2013; 27: /04/as DOI 10.1038/leu.2013.119.
15. Meggendorfer M, Bacher U, Alpermann T, et al. setbp1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), asxl1 and CBL mutations. Leukemia 2013;27:1852-1860. Prepublished on 2013/05/01 as DOI 10.1038/leu.2013.133.
16. Laborde RR, Patnaik MM, Lasho TL, et al. setbp1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: Independent prognostic impact in CMML. Leukemia 2013;27:2100-2102. Prepublished on 2013/04/06 as DOI 10.1038/leu.2013.97.
17. Makishima H, Yoshida K, Nguyen N, et al. Somatic setbp1 mutations in myeloid malignancies. Nat Genet 2013;45:942-946. Prepublished on 2013/07/09 as DOI 10.1038/ng.2696.